Helix BioPharma Corp. announced that it has appointed Dr. Zbigniew Markowski as Chief Executive Officer, replacing Mr. Gary Littlejohn who was serving as Interim CEO. Dr. Markowski comes with a diversified experience, having had a career in business, university and government.

Among others, from 2006 until January 10, 2016 he served as Chairman of O.M. Finance Ltd; from 1998 to 2002, as vice-chairman of Prokom Investments SA, where he was responsible for the financial and pharmaceutical sectors and as Member of the Board of BIOTON SA; from 1993 to 2005 he was a leading coordinator for more than a dozen initial public offerings of Polish companies listed on the WSE. Mr. Yvon Bastien announced his resignation as Chairman of the board and will be replaced by Dr. Sven Rohmann, MD, PhD, MBA. This change, along with Dr. Markowski's appointment as CEO, are effective January 18, 2016.

Mr. Littlejohn will assist Dr. Markowski with a transition plan.